Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.58 |
| ▸ | LTA4H | P09960 | 4/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667235 | 0.90 | PARP15 (0.55) | PARP15PARP10LTA4HPARP2 | |
| SCHEMBL3251238 | 0.81 | TDP1 (0.68) | LTA4HSLC6A4 | |
| SCHEMBL30674540 | 0.81 | NFE2L2 (0.70) | GRM2HPGD | |
| SCHEMBL21579077 | 0.81 | PARP10 (0.58) | PARP15PARP10PARP2GRM2HPGD | |
| SCHEMBL81903 | 0.81 | PARP15 (0.58) | PARP15PARP10PARP2GRM2HPGD | |
| SCHEMBL2657957 | 0.81 | NFE2L2 (0.69) | PARP15PARP10PARP2GRM2HPGD | |
| SCHEMBL3726896 | 0.81 | PARP10 (0.63) | PARP15PARP10PARP2GRM2HPGD | |
| SCHEMBL21579020 | 0.81 | PARP10 (0.58) | PARP15PARP10PARP2GRM2HPGD | |
| SCHEMBL21578972 | 0.81 | PARP10 (0.63) | PARP15PARP10PARP2GRM2HPGD | |
| SCHEMBL385757 | 0.81 | PARP10 (0.58) | PARP15PARP10PARP2GRM2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | VERNALIS RESEARCH LIMITED. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | VERNALIS RESEARCH LIMITED (GB) | 2007-07-26 | — | — | US | disclosed |
| EP-1618105-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2004096794-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181939-A1 | Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated Disorders | CNR1, CNR2, GPR119 | PARP15 3282/4885PARP10 3012/4885LTA4H 4127/4885 |
| US-20070173486-A1 | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs | CNR1, CNR2, GPR119 | PARP15 3506/4885PARP10 3453/4885LTA4H 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.